MarketPR

Lisata Therapeutics (LSTA) files Delaware suit against Kuva Labs, cuts 72% of staff after merger termination

8/6/2026

The collapse of Lisata Therapeutics' planned combination with Kuva Labs has moved into the courts.

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) filed suit in the Delaware Court of Chancery on Tuesday, alleging that Kuva Labs and its subsidiary Kuva Acquisition Corp breached the merger agreement dated March 6, 2026.

In focus for the tape: the $2 million termination fee Lisata says it is owed, and whether the board's ongoing strategic review produces a definitive agreement.

The lawsuit and the $2 million claim The filing centers on the March 6, 2026 merger agreement.